구조모아 (StructureMoa)항암 chemical structure spider web
방문향후 6개월 내 primary completion 예정인 활성 임상과 큐레이션·승인 프로그램의 phase 분포입니다. CT.gov completion date 기반 추정이며 공식 readout 일정과 다를 수 있습니다. RSS
큐레이션·FDA·임상 3건 이상 프로그램 2029개 — catalyst 일정과 별도의 전체 파이프라인 스냅샷입니다.
향후 6개월 catalyst 5건 · 타깃·모달리티 분포
활성 recruiting/enrolling 임상 · CT.gov completion 기준 · 상위 80건 표시
| 완료 예정 | 프로그램 | Phase | Status | Endpoint | 신뢰도 | NCT |
|---|---|---|---|---|---|---|
| 2026년 9월 | Rituxan | Phase 2 | Recruiting | The effect of rituximab on cognitive functions assessed by The Symbol Digit Modalities Test; The effect of rituximab on cognitive functions assessed by The Brief Visuospatial Memory Test-Revised; The effect of rituximab on cognitive functions assessed by The California Verbal Learning Test-II; The effect of rituximab on hand functions assessed by The Nine-Hole Peg Test | 보통 | NCT06599307 |
| 2026년 9월 | Humira (adalimumab) | Phase 4 | Recruiting | Number of yearly-quarters of corticosteroid free remission as a measure of treatment efficacy | 신뢰 높음 | NCT03917303 |
| 2026년 9월 | Abatacept | Phase 2 | Recruiting | Number of Major Graft-Related Adverse Events | 보통 | NCT04477629 |
| 2026년 9월 | Humira (adalimumab) | N/A | Recruiting | Crohn's Disease Activity Index | 신뢰 높음 | NCT04859088 |
| 2026년 9월 | Ocrelizumab | Phase 4 | Active, not recruiting | Dynamic Gait Stability | 신뢰 높음 | NCT04387734 |
The effect of rituximab on cognitive functions assessed by The Symbol Digit Modalities Test; The effect of rituximab on cognitive functions assessed by The Brief Visuospatial Memory Test-Revised; The effect of rituximab on cognitive functions assessed by The California Verbal Learning Test-II; The effect of rituximab on hand functions assessed by The Nine-Hole Peg Test
NCT06599307Number of yearly-quarters of corticosteroid free remission as a measure of treatment efficacy
NCT03917303Number of Major Graft-Related Adverse Events
NCT04477629Crohn's Disease Activity Index
NCT04859088Dynamic Gait Stability
NCT04387734향후 6개월 내 primary completion 예정인 활성 임상과 큐레이션·승인 프로그램의 phase 분포입니다. CT.gov completion date 기반 추정이며 공식 readout 일정과 다를 수 있습니다. RSS
큐레이션·FDA·임상 3건 이상 프로그램 2029개 — catalyst 일정과 별도의 전체 파이프라인 스냅샷입니다.
향후 6개월 catalyst 5건 · 타깃·모달리티 분포
활성 recruiting/enrolling 임상 · CT.gov completion 기준 · 상위 80건 표시
| 완료 예정 | 프로그램 | Phase | Status | Endpoint | 신뢰도 | NCT |
|---|---|---|---|---|---|---|
| 2026년 9월 | Rituxan | Phase 2 | Recruiting | The effect of rituximab on cognitive functions assessed by The Symbol Digit Modalities Test; The effect of rituximab on cognitive functions assessed by The Brief Visuospatial Memory Test-Revised; The effect of rituximab on cognitive functions assessed by The California Verbal Learning Test-II; The effect of rituximab on hand functions assessed by The Nine-Hole Peg Test | 보통 | NCT06599307 |
| 2026년 9월 | Humira (adalimumab) | Phase 4 | Recruiting | Number of yearly-quarters of corticosteroid free remission as a measure of treatment efficacy | 신뢰 높음 | NCT03917303 |
| 2026년 9월 | Abatacept | Phase 2 | Recruiting | Number of Major Graft-Related Adverse Events | 보통 | NCT04477629 |
| 2026년 9월 | Humira (adalimumab) | N/A | Recruiting | Crohn's Disease Activity Index | 신뢰 높음 | NCT04859088 |
| 2026년 9월 | Ocrelizumab | Phase 4 | Active, not recruiting | Dynamic Gait Stability | 신뢰 높음 | NCT04387734 |
The effect of rituximab on cognitive functions assessed by The Symbol Digit Modalities Test; The effect of rituximab on cognitive functions assessed by The Brief Visuospatial Memory Test-Revised; The effect of rituximab on cognitive functions assessed by The California Verbal Learning Test-II; The effect of rituximab on hand functions assessed by The Nine-Hole Peg Test
NCT06599307Number of yearly-quarters of corticosteroid free remission as a measure of treatment efficacy
NCT03917303Number of Major Graft-Related Adverse Events
NCT04477629Crohn's Disease Activity Index
NCT04859088Dynamic Gait Stability
NCT04387734